Effects of Sodium-glucose Cotransporter 2 Inhibitors on Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2020 Feb 22

PMID 32083798

Citations 33

Authors

Baodi Xing

Yuhang Zhao

Bingzi Dong

Yue Zhou

Wenshan Lv

Wenjuan Zhao

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Non-alcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus. Currently, some studies have found that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve non-alcoholic fatty liver in addition to its hypoglycemic effect. Thus, we undertook a meta-analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLD.

Materials And Methods: PubMed, Embase and the Cochrane Library were searched for randomized controlled trials of SGLT2 inhibitors in patients with NAFLD and type 2 diabetes mellitus up to 1 October 2019. Differences were expressed as weight mean difference (WMD) with 95% confidence interval (CI) for continuous outcomes. The I statistic was applied to evaluate the heterogeneity of studies.

Results: A total of six trials including 309 patients were selected into our meta-analysis. SGLT2 inhibitors could reduce alanine aminotransferase (WMD -11.05 IU/L, 95% CI -19.85, -2.25, P = 0.01) and magnetic resonance imaging proton density fat fraction (WMD -2.07%, 95% CI -3.86, -0.28, P = 0.02). However, SGLT2 inhibitors did not reduce aspartate aminotransferase (WMD -1.11 IU/L, 95% CI -2.39, 0.17, P = 0.09). In addition, secondary outcomes, such as bodyweight and visceral fat area, were also reduced (WMD -1.62 kg, 95% CI -2.02, -1.23, P < 0.00001; WMD -19.98 cm , 95% CI -27.18, -12.79, P < 0.00001, respectively).

Conclusions: SGLT2 inhibitors can significantly decrease alanine aminotransferase and liver fat, accompanied with weight loss, which might have a positive effect on fatty liver in patients with type 2 diabetes mellitus. The limitation is that the sample size of the studies was small. Therefore, more large randomized controlled trials specified on NAFLD are required to evaluate these results.

Citing Articles

Targeting ketone body metabolism to treat fatty liver disease.

Kwon S, Jeyaratnam R, Kim K J Pharm Pharm Sci. 2024; 27:13375.

PMID: 39403635 PMC: 11471530. DOI: 10.3389/jpps.2024.13375.

Assessing the Metabolic and Physical Effects of Combined DPP4 and SGLT2 Inhibitor Therapy in Patients with Type-2 Diabetes Mellitus: An Observational Prospective Pilot Study.

Nagayama A, Inokuchi T, Ashida K, Inada C, Homma T, Miyazaki H JMA J. 2024; 7(3):387-400.

PMID: 39114607 PMC: 11301034. DOI: 10.31662/jmaj.2023-0214.

Applications of SGLT2 inhibitors beyond glycaemic control.

OHara D, Lam C, McMurray J, Yi T, Hocking S, Dawson J Nat Rev Nephrol. 2024; 20(8):513-529.

PMID: 38671190 DOI: 10.1038/s41581-024-00836-y.

Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.

Ong Lopez A, Pajimna J Sci Rep. 2024; 14(1):2122.

PMID: 38267513 PMC: 10808406. DOI: 10.1038/s41598-024-52603-5.

Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.

Cheng P, Chen W, Hou C, Lin C, Chang M, Wang C Clin Mol Hepatol. 2023; 30(1):16-36.

PMID: 37793641 PMC: 10776290. DOI: 10.3350/cmh.2023.0315.

References

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

Noureddin M, Lam J, Peterson M, Middleton M, Hamilton G, Le T . Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58(6):1930-40. PMC: 4819962. DOI: 10.1002/hep.26455. View

Eriksson J, Lundkvist P, Jansson P, Johansson L, Kvarnstrom M, Moris L . Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018; 61(9):1923-1934. PMC: 6096619. DOI: 10.1007/s00125-018-4675-2. View

Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N . Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. PMC: 2928471. DOI: 10.1056/NEJMoa0907929. View

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y . Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013; 715(1-3):246-55. DOI: 10.1016/j.ejphar.2013.05.014. View

Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E . SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2018; 19:1-12. PMC: 6323192. DOI: 10.1016/j.molmet.2018.10.009. View

Kim J, Lee M, Kim S, Kim S, Lee B, Kang E . Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk. Diabetes Obes Metab. 2018; 21(4):801-811. DOI: 10.1111/dom.13577. View

Cotter D, Ercal B, Huang X, Leid J, dAvignon D, Graham M . Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest. 2014; 124(12):5175-90. PMC: 4348980. DOI: 10.1172/JCI76388. View

10.

Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W . The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One. 2016; 11(1):e0146337. PMC: 4701474. DOI: 10.1371/journal.pone.0146337. View

11.

Mudaliar S, Polidori D, Zambrowicz B, Henry R . Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. Diabetes Care. 2015; 38(12):2344-53. DOI: 10.2337/dc15-0642. View

12.

Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S . Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes Metab. 2017; 20(2):438-442. DOI: 10.1111/dom.13061. View

13.

Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W . Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig. 2020; 11(5):1238-1247. PMC: 7477503. DOI: 10.1111/jdi.13237. View

14.

Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P . Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34(5):1139-44. PMC: 3114489. DOI: 10.2337/dc10-2229. View

15.

Yamashita H, Takenoshita M, Sakurai M, Bruick R, Henzel W, Shillinglaw W . A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A. 2001; 98(16):9116-21. PMC: 55382. DOI: 10.1073/pnas.161284298. View

16.

Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M . Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014; 4:e125. PMC: 5189930. DOI: 10.1038/nutd.2014.20. View

17.

Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

18.

Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, Kushiyama A . Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015; 7:104. PMC: 4653899. DOI: 10.1186/s13098-015-0102-8. View

19.

Kabil S, Mahmoud N . Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. Eur J Pharmacol. 2018; 828:135-145. DOI: 10.1016/j.ejphar.2018.03.043. View

20.

Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L . Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2009; 30(10):999-1009. DOI: 10.1111/j.1365-2036.2009.04122.x. View